|
|
|
European Biopharmaceutical Review
|
|
The first documented administration of insulin as an intervention
in diabetes was in 1922. A relatively crude extract from bovine pancreas
was injected into a 14-year-old boy in Toronto, and, although the first
injection was not entirely without complications, this intervention
ultimately saved his life. The subsequent impact of this discovery on
the lives of countless patients and our industry has been, to say the
least, transformational. Fast forward a century to 2022, and the
biosimilars of biopharmaceutically manufactured, synthetic insulins will
likely be mainstay therapies for diabetes, as Syneos Health's Rafal
Kokolus, Dr Doug Niven, and Rohit Sood discuss how the illness joins the
list of conditions for which all stakeholders are transitioning towards
biosimilar adoption.
If the rapidly expanding and often complex biosimilars universe is
not quite fully in focus for you yet, then articles in the summer 2018
edition of EBR will provide excellent overviews of the state-of-
the-art in defining by sequence (Dr Richard Easton and Dr Andrew Reason
at BioPharmaSpec) and protecting via optimal patent and commercial
strategies for these high-value ‘affordable’ biological therapeutics,
distinct in sequence and synthesis, yet ‘highly similar’ in efficacy and
safety to first generation proprietary forms of which they are
effectively ‘functional generics’ (Boult Wade Tennant’s Jennifer
O’Farrell, and Finnegans’ Sanya Sukduang and Thomas J Sullivan).
The first ever biosimilar drug product approval (by the EMA in
2006) was for a hormone therapy, omnitrope (somatropin), although the
first biosimilar insulin hormone was only approved as recently as 2014.
Antibody biosimilars, ‘adopted’ by the EMA and FDA more recently, have
made much more ‘noise’, arguably because of the premium priced
proprietary market pioneers they can replace. Three articles in this
edition of EBR focus on antibodies as the targeting component of
antibody-drug conjugates (ADCs) in cancer therapy (the team from Aptamer
Group, and Dr Neil Butt from IONTAS). ADCs are an increasingly
important drug class in oncology, evidenced by the fact that, according
to Professor Andreas Pahl from Heidelberg Pharma, more than 70 are now
in clinical trials.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Annual General Meeting of Gerresheimer AG approves dividend increase to EUR 1.20 per share
Duesseldorf, June 24, 2020—Payment of a dividend of EUR 1.20 per share was approved at the virtual Annual General Meeting of Gerresheimer AG.
More info >> |
|
 |
White Papers |
 |
|
The Power of Execution in Clinical Research
Medpace
Medpace, long known for its excellence in conducting Phase I-IV studies
on a global platform, is particularly noted for its therapeutic
excellence. When that expertise is combined with operational precision,
the results are nothing short of stellar. The Medpace full-service
outsourcing approach – combined with therapeutic expertise, regulatory
know how, and global presence – delivers clinical studies with an
industry recognized track record.
More info >> |
|
 |
Industry Events |
 |
12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
8-11 February 2021, Vienna, Austria
In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >> |
|
|
.jpg)
